<source id="ssofq"><menu id="ssofq"></menu></source>
<source id="ssofq"><mark id="ssofq"></mark></source>
<source id="ssofq"><mark id="ssofq"></mark></source>
About HUILUN

Founded in 2004, Shanghai Huilun Pharmaceutical Co., Ltd. (Huilun Pharma) is a high-tech enterprise dedicating to R&D and technical services in the area of innovative small molecule medicine and generic drugs.

Following clinical value guideline, Huilun Pharma has engaged in R&D in various fields spanning respiratory, cardiovascular, oncology, andrology, gynecology, viral, digestive and nervous system diseases, and has a rich pipeline.

The company has a professional team with a deep understanding of the clinical value of drugs and industry development. The operation management team and core technical positions are led by executives and senior experts with rich industry experience global wise.

Integrating R&D, manufacturing and marketing together, Huilun Pharma has a complete operation system from pre-clinical clinical candidate discovery to formulation development, and from clinical research to drug commercialization. Huilun Pharma has invested in R&D continually with high revenue ratio since the inception and is well-equipped. In line with international standards, the manufacturing center has a strict quality management system, to guarantee the quality of drugs. The marketing center has a matured and skillful marketing team, which covers 31 provinces and autonomous regions in Great China area.

At present, more than 80 domestic and global patent applications have been filed. More than 10 generic drugs in different therapeutical fields have been approved and put on the market. These include 2 exclusive products and 2 first-time made generic drugs. In addition, Huilun Pharma also has more than 10 Class II new drugs and high-end generic drugs in pipeline. More importantly, Huilun Pharma has a number of Class I drug candidates in pipeline as well, and three IND applications of Class I drug candidate have been authorized by NMPA. In the meantime, 20 clinical studies are on-going co-currently.

Up to now, Huilun Pharma has received a lot of funding and awards from various sources. This includes funding support from National Science and Technology Major Project, the Ministry of Science and Technology Innovation Fund for Small and Medium-sized Enterprises, Science and Technology Innovation Action Plan in Shanghai, Shanghai Pudong New Area Science and Technology Development Fund, and Zhangjiang Science City's 2020 Major Industrial Project Support. Huilun Pharma has also received awards in many entitles, such as High-tech Enterprise (2012-2023), 2022 Shanghai Science and Technology “Little Giant” Cultivation Enterprise, 2021-2023 Shanghai Patent Work Pilot Unit, Shanghai“Specialized, Special and New”Enterprise (2021-2023), Shanghai Pudong New Area Corporate R&D Institution, and 2021 Minhang District Key Enterprise.

Based on the established integrated "R&D-manufacture-market" operation system, Huilun Pharma will firmly stick to R&D-driven principle, adhere to the orientated clinical guidelines, provide high quality health services to human beings, and strive to become a first-class pharmaceutical company in China.

Company History
Enterprise development history
milestone
milestone1
milestone2
Culture and values
Agility

Agility

Innovation

Innovation

>Be Realistic

Be Realistic

Collaboration

Collaboration

Ownership

Ownership

Agility

Agility

Innovation

Innovation

>Be Realistic

Be Realistic

Collaboration

Collaboration

Ownership

Ownership

Our Honor

2012 Certified as Shanghai High- and New-Technology Enterprise。

2015 Accredited as Pudong New Area Corporate R&D Institution by Shanghai Pudong Science and Technology Committee

2017 Ranked Top 100 in China Drug R&D Comprehensive Strength

2017 Identified as Shanghai Patent Work Pilot Unit by Shanghai Intellectual Property Administration

2018 Recognized as High-tech “Little Giant” Cultivation Enterprise by Shanghai Science and Technology Committee

2018 Sponsored by Shanghai Science and Technology Innovation Action Plan

2019 Ranked Top 100 in China Chemical Drug R&D Comprehensive Strength

2020 Ranked Top 100 in 2020 China Innovative Pharmaceutical Enterprises

2021 Listed among 2021 Key Enterprises in Minhang District and granted the title of Most Promising Startup.

2021 Recognized as Enterprise with Equity Guide Fund Investment from Hubei Province.

2021 Recognized as Outstanding Enterprise Attracted by Investment Policy in Zhijiang City

2021 Ranked Top 10 Innovative Enterprises in Taizhou Pharmaceutical High-tech District

高清性色生活片久久久_杨幂玩弄高潮在线_中文人妻中出精品视频在线_欧美一级无片在线观看
<source id="ssofq"><menu id="ssofq"></menu></source>
<source id="ssofq"><mark id="ssofq"></mark></source>
<source id="ssofq"><mark id="ssofq"></mark></source>